Unichem receives USFDA approval for Quetiapine ER Tablets

16 Aug 2022 , 10:50 AM

Unichem Laboratories has received ANDA approval for its Quetiapine Extended-Release Tablets USP, 50 mg, 150 mg, 200 mg, 300 mg, and 400 mg from the United States Food and Drug Administration (USFDA) to market a generic version of SEROQUEL XR? (Quetiapine) Tablet, Extended Release, 50 mg, 150 mg, 200 mg, 300 mg, and 400 mg of AstraZeneca Pharmaceuticals LP. Quetiapine Extended-Release Tablets are indicated for the treatment of Schizophrenia, Bipolar disorder and adjunctive treatment of Major Depressive Disorder (MDD). The product will be commercialized from Unichems Goa Plant.Powered by Capital Market – Live News